Adalimumab for juvenile idiopathic arthritis and for fistulising Crohn’s disease

PHARMAC is pleased to announce the approval of a proposal to widen access to adalimumab (Humira and HumiraPen) to include juvenile idiopathic arthritis and fistulising Crohn’s disease, and to list a 20 mg strength of Humira, from 1 July 2013, through an agreement with AbbVie Limited.